|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The ORION statement: guidelines for transparent reporting of outbreak reports and intervention studies of nosocomial infection显示文摘 | Sheldon P Stone Ben S Cooper Chris C Kibbler Barry D Cookson Jenny A Roberts Graham F Medley Georgia Duckworth Rosalind Lai Shah Ebrahim Erwin M Brown Phil J Wiffen Peter G Davey | 2007 | The Lancet Infectious Diseases2007，，4： | 1 |
| 2 | Physiological and nutritional regulation of enzymes of triacylglycerol synthesis显示文摘 | Rosalind A C Lewin T M Deborah M M | 2000 | Ann Rev Nutr2000，20，： | 1 |
| 3 | Senior travellers: Tourism activi- ties and shopping behav iours 显示文摘 | Littrell M A Rosalind C P | 2004 | Journal of Vacation Market- ing2004，10，4： | 1 |
| 4 | Glycophorin A: Band 3aid 显示文摘 | Rosalind C Williamson Ashley M Toye | 2008 | Blood Cells Molecules and Diseases2008，41，1： | 1 |
| 5 | Presentday stresses in Brunei,NW Borneo:Superposition of deltaic and active margin tectonics显示文摘 | Rosalind C K Richard R H Tingay M R P | 2010 | Basin Research2010，22，2： | 1 |
| 6 | Serotonin and Parkinson's disease: on movement, mood, and madness 显示文摘 | Susan H Rosalind C Jonathan M | 2009 | Movement Disorders2009，24，9： | 1 |
| 7 | The two faces of dominance:The differential effect of ingroup superiority and outgroup inf eriority on dominant-group identity and group esteem显示文摘 | ROSALIND M C BRIAN S L ERIC D K | 2007 | Journal of Experimental Social Psychology2007，12，： | 1 |
| 8 | Clinical utilities and end-user experience of pharmacogenomics:39 mo of clinical implementation experience in an Australian hospital setting显示文摘BACKGROUND Pharmacogenomics(PG)testing is under-utilised in Australia.Our research provides Australia-specific data on the perspectives of patients who have had PG testing and those of the clinicians involved in their care,with the aim to inform wider adoption of PG into routine clinical practice.AIM To investigate the frequency of actionable drug gene interactions and assess the perceived utility of PG among patients and clinicians.METHODS We conducted a retrospective audit of PG undertaken by 100 patients at an Australian public hospital genetics service from 2018 to 2021.Via electronic surveys we compared and contrasted the experience,understanding and usage of results between these patients and their clinicians.RESULTS Of 100 patients who had PG,84% were taking prescription medications,of which 67% were taking medications with actionable drug-gene interactions.Twenty-five out of 81 invited patients and 17 out of 89 invited clinicians completed the surveys.Sixty-eight percent of patients understood their PG results and 48% had medications changed following testing.Paired patient-clinician surveys showed patient-perceived utility and experience was positive,contrasting their clinicians’hesitancy on PG adoption who identified insufficient education/training,lack of clinical support,test turnaround time and cost as barriers to adoption.CONCLUSION Our dichotomous findings between the perspectives of our patient and clinician cohorts suggest the uptake of PG is likely to be driven by patients and clinicians need to be prepared to provide information and guidance to their patients. | Rosalind Moxham Andrew Tjokrowidjaja Sophie Devery Renee Smyth Alison McLean Darren M Roberts Kathy H C Wu | 2023 | World Journal of Medical Genetics2023，11，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员